Hyperbaric Oxygen Therapy Does Not Have a Negative Impact on Bone Signaling Pathways in Humans

Area of Science:

• Bone Biology and Metabolism
• Hyperbaric Medicine
• Biomarker Research

Background:

• Oxygen plays a role in bone remodeling, with preclinical data suggesting hyperoxia may harm bone cells.
• The clinical impact of hyperoxia on bone homeostasis remains unclear.
• Wnt and RANKL pathways are crucial for maintaining bone health.

Purpose of the Study:

• To investigate the effects of hyperbaric oxygen therapy (HBOT) on serum biomarkers of bone homeostasis.
• To assess the impact of HBOT on the Wnt and RANKL signaling pathways.

Main Methods:

• Prospective study of 20 patients undergoing HBOT for various conditions.
• Measurement of serum hypoxia-inducible factor 1-α (HIF1-α), osteoprotegerin (OPG), RANKL, sclerostin, and dickkopf-1 (DKK1) at baseline and post-HBOT.
• Specific immunoassays were used for biomarker quantification.

Main Results:

• Serum HIF-1α levels significantly increased post-HBOT (p=0.028).
• No significant changes were observed in serum levels of OPG, RANKL, sclerostin, or DKK1 following HBOT.
• These findings were consistent across different patient diagnoses.

Conclusions:

• HBOT does not appear to have detrimental effects on bone homeostasis biomarkers.
• The study provides evidence against concerns regarding hyperoxia's negative impact on bone cells in a clinical setting.
• Further research may explore the nuanced effects of HBOT on bone metabolism.